|
Match
|
Document |
Document Title |
|
|
7354706 |
Use of photopolymerization for amplification and detection of a molecular recognition event
The invention provides methods to detect molecular recognition events. The invention also provides methods to detect the presence of or identify a target species based on its interaction with one...
|
|
|
7344722 |
Cold-adapted influenza virus
The cold-adapted master strain A/Ann Arbor/6/60 7PI (H2N2) and progenitor wild type E2(3) viral strains have been deposited and their genomic sequences identified. Seven nucleotide differences were...
|
|
|
7339037 |
Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
The invention provides a method of inhibiting prophylactically or therapeutically an influenza viral infection in a host. The method comprises instilling into or onto a host a cell producing an...
|
|
|
7316813 |
Influenza vaccine composition
An inactivated influenza virus preparation is described which comprises a haemagglutinin antigen stabilized in the absence of thiomersal, or at low levels of thiomersal, wherein the haemagglutinin...
|
|
|
7279167 |
Infectious Salmon Anaemia virus vaccine
This invention relates to Infectious Salmon Anaemia Virus (ISAV) antigenic polypeptides and nucleic acid molecules encoding them, as well as vaccines, transformed cells and transgenic fish. The...
|
|
|
7262045 |
Methods of producing influenza vaccine compositions
Methods and compositions for the optimization of production of influenza viruses suitable as influenza vaccines are provided.
|
|
|
7226775 |
Method of removing endotoxin from vaccines
A method of removing bacterial endotoxin from a pharmaceutical process solution is disclosed. In one embodiment, the method comprises treating the solution with a surfactant effective to dissociate...
|
|
|
7201910 |
Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines
The present invention provides the use of nucleic acid sequences and/or amino acid sequences in the preparation of a vaccine for the protection of fish against infectious salmon anaemia virus....
|
|
|
7201909 |
Cold-adapted equine influenza viruses
The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza...
|
|
|
7189800 |
Replikin peptides in rapid replication of glioma cells and in influenza epidemics
Peptides of influenza virus hemagglutinin protein and Plasmodium falciparum malaria antigen, antibodies specific for the peptides, influenza vaccines, malaria vaccines and methods of stimulating...
|
|
|
7169394 |
Mycoplasma hyopneumoniae bacterin vaccine
The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition...
|
|
|
7135180 |
Preservation of bioactive materials by freeze dried foam
This invention provides methods and compositions to preserve bioactive materials in a dried foam matrix. Methods provide non-boiling foam generation and penetration of preservative agents at...
|
|
|
7128917 |
Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines
The present invention provides the use of nucleic acid sequences and/or amino acid sequences in the preparation of a vaccine for the protection of fish against infectious salmon anaemia virus....
|
|
|
7090853 |
Noscapine derivatives as adjuvant compositions and methods of use thereof
An adjuvant composition comprising noscapine and its derivatives, for use in the treatment of tumors, cancer, as an adjuvant for vaccines.
|
|
|
7056521 |
Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
The present invention provides parenteral adjuvants comprising detoxified mutants of bacterial ADP-ribosylating toxins, particularly those from pertussis (PT), cholera (CT), and heat-labile E....
|
|
|
7052701 |
Inactivated influenza virus vaccine for nasal or oral application
The invention relates to nasal or oral administration of a compound containing inactivated influenza virus antigen and aluminum as adjuvant for the prophylaxis of influenza virus infections. Said...
|
|
|
7018638 |
Mycoplasma hyopneumoniae bacterin vaccine
The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition...
|
|
|
6974686 |
Recombinant tryptophan mutants of influenza
Recombinant PB2 tryptophan variant influenza viruses, RNA, cDNA and vectors are provided. Also provided are immunogenic compositions containing the variant viruses, methods of producing such...
|
|
|
6951752 |
Method for large scale production of virus antigen
The present invention provides improved methods of production of viral antigen on a culture of adherent cells bound to a microcarrier, wherein the methods provide for increased viral antigen yield...
|
|
|
6887484 |
Vaccine composition containing a promoter peptide
A vaccine having a good vaccination effect, which comprises an antigen; a peptide selected from the group consisting of a peptide having the amino acid sequence of SEQ ID NO: 1, a peptide having...
|
|
|
6872395 |
Viruses comprising mutant ion channel protein
A method to prepare viruses lacking ion channel activity is provided.
|
|
|
6866853 |
Interferon inducing genetically engineered attenuated viruses
The present invention relates to genetically engineered attenuated viruses and methods for their production. In particular, the present invention relates to engineering live attenuated viruses...
|
|
|
6843996 |
Immunogenic composition comprising an influenza virus with a temperature sensitive PB2 mutation
Recombinant PB2 variant influenza viruses, RNA, cDNA and vectors are provided. Also provided are immunogenic compositions containing the variant viruses, methods of producing such viruses and...
|
|
|
6814971 |
Adjuvants for use in vaccines
The invention relates to adjuvants that contain a lecithin, an oil and an amphiphilic surfactant and that are capable of forming a stable oil-in-water emulsion vaccine so as to minimize local...
|
|
|
6800288 |
Recombinant influenza A viruses
The invention relates to a recombinant NS gene of an influenza A virus comprising a functional RNA binding domain and a gene sequence modification after nucleotide position 400 of the NS1 gene...
|
|
|
6793928 |
Vaccines with an LTB adjuvant
The present invention relates to a vaccine containing at least one particulate immunogen and an adjuvanting amount of B subunits of heat-labile enterotoxin characteristic of E. Coli . More in...
|
|
|
6669943 |
Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated...
|
|
|
6558674 |
Polynucleotide vaccine formulation against pathologies of the horse
Disclosed and claimed is: an immunogenic or vaccine composition for inducing in an equine host an immunological response against equine pathologies containing at least one plasmid that contains and...
|
|
|
6544526 |
Equine herpesvirus glycoproteins
A vaccine for the selective immunization of horses against EHV4 and/or EHV1 is provided comprising at least one of (i) EHV4 virus wherein a portion of the gG gene of the EHV4 virus that elicits a...
|
|
|
6497883 |
Porcine circovirus recombinant poxvirus vaccine
What is described is a recombinant poxvirus, such as avipox virus, containing foreign DNA from porcine circovirus 2. What are also described are immunological compositions containing the...
|
|
|
6475770 |
Processes for preparation of Marek's Disease using continuous mammalian cell lines
The present invention relates to mammalian cell lines which efficiently support the growth and productive infection of Marek's Disease Virus at high titers. The present invention also relates to...
|
|
|
6471964 |
DNA encoding structural protein-1 of infectious Salmon Anaemia virus and uses thereof
The present invention concerns a nucleic acid encoding a structural protein of Infectious Salmon Anaemia Virus (ISAV) designated as Structural Protein-1 (SP-1), the isolated SP-1 protein, and use...
|
|
|
6464984 |
Avian polynucleotide vaccine formula
An avian plasmid vaccine contains a plasmid, and a pharmaceutically acceptable carrier. The plasmid contains and expresses in vivo in an avian host cell a nucleic acid molecule having a sequence...
|
|
|
6406698 |
Pharmaceutical composition comprising serum amyloid P component for prophylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components
Pharmaceutical compositions comprising a protein serum amyloid P component (SAP) capable of binding viruses, especially myxovirus, e.g. influenza viruses and thereby preventing the transmission and...
|
|
|
6403363 |
Method of preservation of vaccines with polybiguanide
A method for preventing or reducing bacterial contamination of a viral vaccine is disclosed. The method comprises adding an effective preserving amount of a polybiguanide-containing preservative...
|
|
|
6387373 |
Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
The present invention features an adjuvanted vaccine, and methods for preparing an adjuvanted vaccine, preferably for immunizing against influenza, where the adjuvant is a lipid vesicle, and...
|
|
|
6372223 |
Influenza virus vaccine composition
This invention describes an influenza virus vaccine containing an influenza virus antigen obtained from a cell culture, with an influenza virus antigen content between 1 μg and 5 μg per dose and...
|
|
|
6344354 |
Influenza virus replicated in mammalian cell culture and vaccine production
The invention provides replication of high growth influenza virus strains, derived from clinical isolates, in cultured mammalian cells by infecting the mammalian cells with the high growth strains...
|
|
|
6342226 |
Method for increasing immunogenicity, product obtained and pharmaceutical compositions
The present invention relates to a method for increasing the immunogenicity of an antigen, characterized in that the antigen is combined via stable interactions with a particulate vector, said...
|
|
|
6299874 |
Method of treatment
A method of producing active immunity against a viral disease in an animal subject comprises administering to the subject a vaccine conjugate consisting essentially of a live virus and a...
|
|
|
6251404 |
Method of producing a vaccine which raises an immunological response against a virus causing a porcine respiratory and reproductive disease
The present invention provides a vaccine which protects pigs from a virus and/or an infectious agent causing a porcine respiratory and reproductive disease, a method of protecting a pig from a...
|
|
|
6231860 |
Stabilizers for live vaccines
Stabilizers for live vaccines and attenuated mono- or multivalent live vaccines, stabilized vaccines containig such stabilizers, and methods for preparing such vaccines, are disclosed. Said...
|
|
|
6221362 |
Avian polynucleotide formula
The avian vaccine formula comprises at least three polynucleotide vaccine valencies each comprising a plasmid integrating, so as to express it in vivo in the host cells, a gene with one avian...
|
|
|
6217883 |
Porcine circovirus and paravovirus vaccine
The invention relates to antigenic preparations and vaccines directed against the porcine multisystemic wasting syndrome (PMWS), comprising at least one porcine circovirus antigen, preferably type...
|
|
|
6207171 |
Polyphosphazene microspheres
A soluble polyphosphazene polyelectrolyte immunoadjuvant is disclosed. In one embodiment, the polymeric adjuvant is poly[di(carboxylatrophenoxy)phosphazene] which is in the form of a microsphere...
|
|
|
6207166 |
Polynucleotide formulation against pathologies of the horse
Disclosed and claimed is: an immunogenic or vaccine composition for inducing in an equine host an immunological response against equine rhinopneumonitis virus (EHV) containing at least one plasmid...
|
|
|
6193983 |
Equine herpesvirus glycoproteins
A vaccine for the selective immunization of horses against EHV4 and/or EHV1 is provided comprising at least one of (i) EHV4 virus wherein a portion of the gG gene of the EHV4 virus that elicits a...
|
|
|
6169175 |
Preparation and use of recombinant influenza A virus M2 construct vaccines
The present invention provides a method of increasing the recombinant expression and solubility of influenza A virus M2 polypeptide comprising nucleic acids encoding variants of the M2 protein of...
|
|
|
6168787 |
Pluripotent vaccine against enveloped viruses
The present invention is directed to compositions and methods for the induction of immune responses in mammals against enveloped animal viruses. More particularly, the invention provides vaccine...
|
|
|
6146873 |
Production of orthomyxoviruses in monkey kidney cells using protein-free media
Viruses from the family Orthomyxoviridae, particularly influenza virus, can grown in monkey kidney cells, particularly Vero Cells, after passaging the cells in a serum-free or protein-free medium....
|